Phys Vivas · oncological
Breakthrough Cancer Pain AND Opioid Titration — Viva Defence
DCE viva defence for Breakthrough Cancer Pain AND Opioid Titration.
On this page
Study tools
Target exams
Breakthrough Cancer Pain AND Opioid Titration Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Breakthrough Cancer Pain AND Opioid Titration. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]
Examiner questions
Q1: "What makes this urgent?" [1]
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]
Q2: "What is your first investigation package?" [2]
"I order tests that change management now, not a scattergun panel." [1] [2]
Q3: "Walk me through treatment." [1]
"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]
Q4: "What is the classic trap?" [2]
"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]
References5ShowHide
- [1]Mercadante S, Candido K, Staats P, Davis M Spinal analgesia in cancer pain management-MASCC general practice recommendations Support Care Cancer, 2025.PMID 40634640
- [2]Mercadante S Once again... breakthrough cancer pain: an updated overview J Anesth Analg Crit Care, 2023.PMID 37480136
- [3]Mercadante S An overview of the current drug treatment strategies for moderate to severe, chronic malignant tumor-related pain Expert Opin Pharmacother, 2024.PMID 37016731
- [4]Kiani CS, Hunt RW Lidocaine Continuous Subcutaneous Infusion for Neuropathic Pain in Hospice Patients: Safety and Efficacy J Pain Palliat Care Pharmacother, 2021.PMID 33793373
- [5]Michenot N, Rostaing S, Baron L, Faure S, et al. [Opioid switch and change of route of administration in cancer patients treated by morphine] Bull Cancer, 2018.PMID 30274680